PMAM
OBIO icon

Picton Mahoney Asset Management’s Orchestra BioMed OBIO Stock Holding History

Picton Mahoney Asset Management’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-78,507
Closed -$781K – 781
2022
Q2 		$781K Hold
78,507
– – 0.03% 561
2022
Q1 		$778K Hold
78,507
– – 0.03% 590
2021
Q4 		$792K Hold
78,507
– – 0.02% 618
2021
Q3 		$777K Hold
78,507
– – 0.03% 565
2021
Q2 		$802K Buy
+78,507
New +$812K 0.02% 580

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Picton Mahoney Asset Management's OBIO Position: Q3 2022 in Review

Picton Mahoney Asset Management sold out of Orchestra BioMed (OBIO) in Q3 2022, closing a stake of 78,507 shares — an estimated $781K sold.

Picton Mahoney Asset Management first reported a position in OBIO in Q2 2021 and held it in 5 quarters. The position peaked at $802K in Q2 2021. 23 funds tracked by Wall St. Rank hold OBIO as of Q3 2022.

  • Picton Mahoney Asset Management reported no remaining Orchestra BioMed position as of Q3 2022 after selling out during the quarter.
  • Picton Mahoney Asset Management sold 78,507 Orchestra BioMed shares in Q3 2022, an estimated $781K.
  • Picton Mahoney Asset Management first reported a position in Orchestra BioMed in Q2 2021 and held it in 5 quarters.
  • Picton Mahoney Asset Management's Orchestra BioMed position peaked at $802K in Q2 2021.
  • 23 funds tracked by Wall St. Rank held Orchestra BioMed as of Q3 2022.

Based on Picton Mahoney Asset Management's 13F filing for Q3 2022, filed 9 Nov 2022.